Armed with a $435M bankroll, Po­laris looks to the next wave of biotech star­tups

Po­laris Part­ners is open­ing up chap­ter 8 in its big book of biotech in­vest­ments.

Man­ag­ing Part­ner Dave Bar­rett an­nounced in a blog post Thurs­day that the ven­ture group closed on Po­laris VI­II with $435 mil­lion in the bank, $35 mil­lion over its tar­get.

That cash will be put to a va­ri­ety of us­es, run­ning from drug de­vel­op­ment through tech­nol­o­gy and tech ser­vices. And they’ll con­tin­ue to work with some high pro­file se­r­i­al biotech ex­ecs and sci­en­tists, like Ka­trine Bosley at Ed­i­tas and ear­li­er at Avi­la, Till­man Gern­gross at Adimab and Gly­coFi, Bob Langer — be­hind a whole range of com­pa­nies like Mo­men­ta — John Mendlein at Ad­nexus and Fate and Phillip Sharp at Al­ny­lam and Sir­tris.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.